Immunotherapy in Alzheimer’s Disease

摘要: Alzheimer’s disease (AD) is the most prevalent proteopathy characterized by dementia that appeals for major concern worldwide. The causative factor imbalance between production and clearance of toxic Aβ peptide (40–43 amino acid long) from brain. Among all therapeutic approaches, prominent one immunotherapy. Both active passive immunotherapies have been worked upon. majority immunization-based methods suffered risks autoimmune inflammation due to cross-reactivity with nontoxic form. However, conventional monoclonal antibody (mAb)-based strategies designed reduce level in brain neutralize effects. A multitude clinical trials are being conducted using approach. Recently, alternative approaches including recombinant fragments emerged as a tool safer more effective therapy. Promising results observed studies employing which include ScFv, BsAb, Fab, gammabodies, intrabodies. Although there failures some these trials, experiences gained them can be used designing better therapeutics. Currently, an urgent need therapeutics target clear off senile plaques limited side effects toxicity.